Highlights
KLSE: NEXGRAM (0096)       NEXGRAM HOLDINGS BHD ACE : Telco&Media
Last Price Today's Change   Day's Range   Trading Volume
0.045   0.00 (0.00%)  0.045 - 0.05  29,608,100
Analyze this stock with MQ Trader system

Financials


Market Cap: 100 Million

Market Cap 100 Million
NOSH 2,230 Million

Latest Audited Result:  31-Jul-2020

Latest Audited Result: 31-Jul-2020
Announcement Date 24-Nov-2020
Next Audited Result: 31-Jul-2021
Est. Ann. Date: 24-Nov-2021
Est. Ann. Due Date: 27-Jan-2022

Latest Quarter:  31-Oct-2020 [#1]

Latest Quarter: 31-Oct-2020 [#1]
Announcement Date 30-Dec-2020
Next Quarter: 31-Jan-2021
Est. Ann. Date: 30-Mar-2021
Est. Ann. Due Date: 01-Apr-2021
QoQ | YoY   95.53%  |    -4,077.61%

Annual (Unaudited) ( EPS: -2.78, P/E: -1.62 )

Revenue | NP to SH 41,277  |  -61,890
RPS | P/RPS 1.85 Cent  |  2.43
EPS | P/E | EY -2.78 Cent  |  -1.62  |  -61.67%
DPS | DY | Payout % 0.00 Cent  |  0.00%  |  - %
NAPS | P/NAPS 0.04  |  1.10
YoY   -182.44%
NP Margin | ROE -148.92%  |  -68.00%
F.Y. | Ann. Date 31-Jul-2020  |  29-Sep-2020

T4Q Result ( EPS: -2.89, P/E: -1.56 )

Revenue | NP to SH 42,220  |  -64,527
RPS | P/RPS 1.89 Cent  |  2.38
EPS | P/E | EY -2.89 Cent  |  -1.56  |  -64.30%
DPS | DY | Payout % 0.00 Cent  |  0.00%  |  - %
NAPS | P/NAPS 0.05  |  0.92
QoQ | YoY   -4.42%  |    -146.15%
NP Margin | ROE -153.44%  |  -59.29%
F.Y. | Ann. Date 31-Oct-2020  |  30-Dec-2020

Annualized Result ( EPS: -0.48, P/E: -9.41 )

Revenue | NP to SH 51,784  |  -10,660
RPS | P/RPS 2.32 Cent  |  1.94
EPS | P/E | EY -0.48 Cent  |  -9.41  |  -10.62%
DPS | DY | Payout % -
NAPS | P/NAPS -
QoQ | YoY   82.78%  |    -4,077.61%
NP Margin | ROE -21.74%  |  -9.80%
F.Y. | Ann. Date 31-Oct-2020  |  30-Dec-2020


Show?  YoY % Horiz. %
Last 10 FY Result
AQR T4Q 31/07/20 31/07/19 31/07/18 31/07/17 31/07/16 31/07/15 30/04/15 30/04/14 30/04/13 30/04/12 CAGR
Revenue 51,784 42,220 41,277 58,341 45,638 53,162 0 0 135,340 102,050 79,677 62,901 -4.97%
  YoY % 22.65% 2.28% -29.25% 27.83% -14.15% 0.00% 0.00% 0.00% 32.62% 28.08% 26.67% -
  Horiz. % 82.33% 67.12% 65.62% 92.75% 72.56% 84.52% 0.00% 0.00% 215.16% 162.24% 126.67% 100.00%
PBT -11,352 -65,579 -62,264 -20,288 -57,581 -11,363 0 0 13,151 14,951 6,593 6,897 -
  YoY % 82.69% -5.32% -206.90% 64.77% -406.74% 0.00% 0.00% 0.00% -12.04% 126.77% -4.41% -
  Horiz. % -164.59% -950.83% -902.77% -294.16% -834.87% -164.75% 0.00% 0.00% 190.68% 216.78% 95.59% 100.00%
Tax 96 795 795 -1,553 -296 -5,489 0 0 -4,173 -5 -6 0 -
  YoY % -87.92% 0.00% 151.19% -424.66% 94.61% 0.00% 0.00% 0.00% -83,360.00% 16.67% 0.00% -
  Horiz. % -1,600.00% -13,250.00% -13,250.00% 25,883.33% 4,933.33% 91,483.33% -0.00% -0.00% 69,550.00% 83.33% 100.00% -
NP -11,256 -64,784 -61,469 -21,841 -57,877 -16,852 0 0 8,978 14,946 6,587 6,897 -
  YoY % 82.63% -5.39% -181.44% 62.26% -243.44% 0.00% 0.00% 0.00% -39.93% 126.90% -4.49% -
  Horiz. % -163.20% -939.31% -891.24% -316.67% -839.16% -244.34% 0.00% 0.00% 130.17% 216.70% 95.51% 100.00%
NP to SH -10,660 -64,527 -61,890 -21,913 -57,864 -16,190 0 0 6,977 14,028 7,358 7,978 -
  YoY % 83.48% -4.26% -182.44% 62.13% -257.41% 0.00% 0.00% 0.00% -50.26% 90.65% -7.77% -
  Horiz. % -133.62% -808.81% -775.76% -274.67% -725.29% -202.93% 0.00% 0.00% 87.45% 175.83% 92.23% 100.00%
Tax Rate - % - % - % - % - % - % - % - % 31.73 % 0.03 % 0.09 % - % -
  YoY % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 105,666.66% -66.67% 0.00% -
  Horiz. % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 35,255.55% 33.33% 100.00% -
Total Cost 63,040 107,004 102,746 80,182 103,515 70,014 0 0 126,362 87,104 73,090 56,004 7.63%
  YoY % -41.09% 4.14% 28.14% -22.54% 47.85% 0.00% 0.00% 0.00% 45.07% 19.17% 30.51% -
  Horiz. % 112.56% 191.06% 183.46% 143.17% 184.84% 125.02% 0.00% 0.00% 225.63% 155.53% 130.51% 100.00%
Net Worth 108,827 108,827 91,013 12,339,400 142,645 19,853,135 21,894,014 194,629 195,355 98,954 89,882 69,415 3.33%
  YoY % 0.00% 19.57% -99.26% 8,550.42% -99.28% -9.32% 11,149.09% -0.37% 97.42% 10.09% 29.48% -
  Horiz. % 156.78% 156.78% 131.11% 17,776.05% 205.49% 28,600.28% 31,540.35% 280.38% 281.43% 142.55% 129.48% 100.00%
Dividend
AQR T4Q 31/07/20 31/07/19 31/07/18 31/07/17 31/07/16 31/07/15 30/04/15 30/04/14 30/04/13 30/04/12 CAGR
Div - 0 - - - - - - - - - - -
  YoY % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -
  Horiz. % - - - - - - - - - - - -
Div Payout % - % - % - % - % - % - % - % - % - % - % - % - % -
  YoY % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -
  Horiz. % - - - - - - - - - - - -
Equity
AQR T4Q 31/07/20 31/07/19 31/07/18 31/07/17 31/07/16 31/07/15 30/04/15 30/04/14 30/04/13 30/04/12 CAGR
Net Worth 108,827 108,827 91,013 12,339,400 142,645 19,853,135 21,894,014 194,629 195,355 98,954 89,882 69,415 3.33%
  YoY % 0.00% 19.57% -99.26% 8,550.42% -99.28% -9.32% 11,149.09% -0.37% 97.42% 10.09% 29.48% -
  Horiz. % 156.78% 156.78% 131.11% 17,776.05% 205.49% 28,600.28% 31,540.35% 280.38% 281.43% 142.55% 129.48% 100.00%
NOSH 2,230,081 2,230,081 2,661,204 2,053,144 1,896,876 1,865,896 1,876,093 1,453,541 1,453,541 758,270 545,736 406,892 25.54%
  YoY % 0.00% -16.20% 29.62% 8.24% 1.66% -0.54% 29.07% 0.00% 91.69% 38.94% 34.12% -
  Horiz. % 548.08% 548.08% 654.03% 504.59% 466.19% 458.57% 461.08% 357.23% 357.23% 186.36% 134.12% 100.00%
Ratio Analysis
AQR T4Q 31/07/20 31/07/19 31/07/18 31/07/17 31/07/16 31/07/15 30/04/15 30/04/14 30/04/13 30/04/12 CAGR
NP Margin -21.74 % -153.44 % -148.92 % -37.44 % -126.82 % -31.70 % - % - % 6.63 % 14.65 % 8.27 % 10.96 % -
  YoY % 85.83% -3.04% -297.76% 70.48% -300.06% 0.00% 0.00% 0.00% -54.74% 77.15% -24.54% -
  Horiz. % -198.36% -1,400.00% -1,358.76% -341.61% -1,157.12% -289.23% 0.00% 0.00% 60.49% 133.67% 75.46% 100.00%
ROE -9.80 % -59.29 % -68.00 % -0.18 % -40.57 % -0.08 % - % - % 3.57 % 14.18 % 8.19 % 11.49 % -
  YoY % 83.47% 12.81% -37,677.78% 99.56% -50,612.50% 0.00% 0.00% 0.00% -74.82% 73.14% -28.72% -
  Horiz. % -85.29% -516.01% -591.82% -1.57% -353.09% -0.70% 0.00% 0.00% 31.07% 123.41% 71.28% 100.00%
Per Share
AQR T4Q 31/07/20 31/07/19 31/07/18 31/07/17 31/07/16 31/07/15 30/04/15 30/04/14 30/04/13 30/04/12 CAGR
RPS 2.32 1.89 1.55 2.84 2.41 2.85 - - 9.31 13.46 14.60 15.46 -24.31%
  YoY % 22.75% 21.94% -45.42% 17.84% -15.44% 0.00% 0.00% 0.00% -30.83% -7.81% -5.56% -
  Horiz. % 15.01% 12.23% 10.03% 18.37% 15.59% 18.43% 0.00% 0.00% 60.22% 87.06% 94.44% 100.00%
EPS -0.48 -2.89 -2.33 -1.07 -3.05 -0.87 0.00 0.00 0.48 1.85 1.27 1.89 -
  YoY % 83.39% -24.03% -117.76% 64.92% -250.57% 0.00% 0.00% 0.00% -74.05% 45.67% -32.80% -
  Horiz. % -25.40% -152.91% -123.28% -56.61% -161.38% -46.03% 0.00% 0.00% 25.40% 97.88% 67.20% 100.00%
DPS 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 -
  YoY % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -
  Horiz. % - - - - - - - - - - - -
NAPS 0.0488 0.0488 0.0342 6.0100 0.0752 10.6400 11.6700 0.1339 0.1344 0.1305 0.1647 0.1706 -17.69%
  YoY % 0.00% 42.69% -99.43% 7,892.02% -99.29% -8.83% 8,615.46% -0.37% 2.99% -20.77% -3.46% -
  Horiz. % 28.60% 28.60% 20.05% 3,522.86% 44.08% 6,236.81% 6,840.56% 78.49% 78.78% 76.49% 96.54% 100.00%
Adjusted Per Share Value based on latest NOSH - 2,230,081
AQR T4Q 31/07/20 31/07/19 31/07/18 31/07/17 31/07/16 31/07/15 30/04/15 30/04/14 30/04/13 30/04/12 CAGR
RPS 2.32 1.89 1.85 2.62 2.05 2.38 - - 6.07 4.58 3.57 2.82 -4.98%
  YoY % 22.75% 2.16% -29.39% 27.80% -13.87% 0.00% 0.00% 0.00% 32.53% 28.29% 26.60% -
  Horiz. % 82.27% 67.02% 65.60% 92.91% 72.70% 84.40% 0.00% 0.00% 215.25% 162.41% 126.60% 100.00%
EPS -0.48 -2.89 -2.78 -0.98 -2.59 -0.73 0.00 0.00 0.31 0.63 0.33 0.36 -
  YoY % 83.39% -3.96% -183.67% 62.16% -254.79% 0.00% 0.00% 0.00% -50.79% 90.91% -8.33% -
  Horiz. % -133.33% -802.78% -772.22% -272.22% -719.44% -202.78% 0.00% 0.00% 86.11% 175.00% 91.67% 100.00%
DPS 0.00 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00 -
  YoY % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -
  Horiz. % - - - - - - - - - - - -
NAPS 0.0488 0.0488 0.0408 5.5332 0.0640 8.9024 9.8176 0.0873 0.0876 0.0444 0.0403 0.0311 3.34%
  YoY % 0.00% 19.61% -99.26% 8,545.62% -99.28% -9.32% 11,145.82% -0.34% 97.30% 10.17% 29.58% -
  Horiz. % 156.91% 156.91% 131.19% 17,791.64% 205.79% 28,625.08% 31,567.85% 280.71% 281.67% 142.77% 129.58% 100.00%
Price Multiplier on Financial Quarter End Date
AQR T4Q 31/07/20 31/07/19 31/07/18 31/07/17 31/07/16 31/07/15 30/04/15 30/04/14 30/04/13 30/04/12 CAGR
Date AQR T4Q 30/07/20 31/07/19 31/07/18 31/07/17 29/07/16 31/07/15 30/04/15 30/04/14 30/04/13 30/04/12 -
Price 0.0350 0.0350 0.0550 0.0150 0.0300 0.0400 0.0500 0.0950 0.1150 0.1200 0.0850 0.1000 -
P/RPS 1.51 1.85 3.55 0.53 1.25 1.40 0.00 0.00 1.24 0.89 0.58 0.65 22.83%
  YoY % -18.38% -47.89% 569.81% -57.60% -10.71% 0.00% 0.00% 0.00% 39.33% 53.45% -10.77% -
  Horiz. % 232.31% 284.62% 546.15% 81.54% 192.31% 215.38% 0.00% 0.00% 190.77% 136.92% 89.23% 100.00%
P/EPS -7.32 -1.21 -2.36 -1.41 -0.98 -4.61 0.00 0.00 23.96 6.49 6.30 5.10 -
  YoY % -504.96% 48.73% -67.38% -43.88% 78.74% 0.00% 0.00% 0.00% 269.18% 3.02% 23.53% -
  Horiz. % -143.53% -23.73% -46.27% -27.65% -19.22% -90.39% 0.00% 0.00% 469.80% 127.25% 123.53% 100.00%
EY -13.66 -82.67 -42.28 -71.15 -101.68 -21.69 0.00 0.00 4.17 15.42 15.86 19.61 -
  YoY % 83.48% -95.53% 40.58% 30.03% -368.79% 0.00% 0.00% 0.00% -72.96% -2.77% -19.12% -
  Horiz. % -69.66% -421.57% -215.60% -362.83% -518.51% -110.61% 0.00% 0.00% 21.26% 78.63% 80.88% 100.00%
DY 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -
  YoY % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -
  Horiz. % - - - - - - - - - - - -
P/NAPS 0.72 0.72 1.61 0.00 0.40 0.00 0.00 0.71 0.86 0.92 0.52 0.59 12.93%
  YoY % 0.00% -55.28% 0.00% 0.00% 0.00% 0.00% 0.00% -17.44% -6.52% 76.92% -11.86% -
  Horiz. % 122.03% 122.03% 272.88% 0.00% 67.80% 0.00% 0.00% 120.34% 145.76% 155.93% 88.14% 100.00%
Price Multiplier on Announcement Date
AQR T4Q 31/07/20 31/07/19 31/07/18 31/07/17 31/07/16 31/07/15 30/04/15 30/04/14 30/04/13 30/04/12 CAGR
Date AQR T4Q 29/09/20 30/09/19 02/10/18 29/09/17 30/09/16 - 30/06/15 30/06/14 28/06/13 28/06/12 -
Price 0.0450 0.0450 0.0450 0.0150 0.0250 0.0400 0.0450 0.0000 0.1000 0.1100 0.0850 0.0900 -
P/RPS 1.94 2.38 2.90 0.53 1.04 1.40 0.00 0.00 1.07 0.82 0.58 0.58 21.52%
  YoY % -18.49% -17.93% 447.17% -49.04% -25.71% 0.00% 0.00% 0.00% 30.49% 41.38% 0.00% -
  Horiz. % 334.48% 410.34% 500.00% 91.38% 179.31% 241.38% 0.00% 0.00% 184.48% 141.38% 100.00% 100.00%
P/EPS -9.41 -1.56 -1.93 -1.41 -0.82 -4.61 0.00 0.00 20.83 5.95 6.30 4.59 -
  YoY % -503.21% 19.17% -36.88% -71.95% 82.21% 0.00% 0.00% 0.00% 250.08% -5.56% 37.25% -
  Horiz. % -205.01% -33.99% -42.05% -30.72% -17.86% -100.44% 0.00% 0.00% 453.81% 129.63% 137.25% 100.00%
EY -10.62 -64.30 -51.68 -71.15 -122.02 -21.69 0.00 0.00 4.80 16.82 15.86 21.79 -
  YoY % 83.48% -24.42% 27.36% 41.69% -462.56% 0.00% 0.00% 0.00% -71.46% 6.05% -27.21% -
  Horiz. % -48.74% -295.09% -237.17% -326.53% -559.98% -99.54% 0.00% 0.00% 22.03% 77.19% 72.79% 100.00%
DY 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 -
  YoY % 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -
  Horiz. % - - - - - - - - - - - -
P/NAPS 0.92 0.92 1.32 0.00 0.33 0.00 0.00 0.00 0.74 0.84 0.52 0.53 11.68%
  YoY % 0.00% -30.30% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -11.90% 61.54% -1.89% -
  Horiz. % 173.58% 173.58% 249.06% 0.00% 62.26% 0.00% 0.00% 0.00% 139.62% 158.49% 98.11% 100.00%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ Δ & YoY Δ figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Trade this stock for as low as 0.05% brokerage. Find out more.
  Like Social Forum Comment
  44 people like this.
 
SeliparJepon Pagi2 dah poyo
21/01/2021 9:12 AM
DRwarrant POTENTIAL 6 SEN TODAY $$ as worsening Covid is DAMN GOOD to NEXGRAM business = $$$

During MCO ..no gaming out let , NO Magnum 4D , No TOTO , NO Genting Casino & what not...

FURTHER MORE WITH GOVERNMENT STIMULUS MONEY / FUND $$$ - MORE LIQUIDITY IN MARKET

SO BURSA/KLSE to be VERY HOT = $$$$$
21/01/2021 9:26 AM
8dragon Nexgram.... Don't ever dream for the share to go up above 5 cents... Not in this 2 months at least..
21/01/2021 2:10 PM
DRwarrant " I have a dream.....( US M Luther King ) "

NEXGRAM to HIT 10 SEN by CNY@Chinese New Year = $$$$$
21/01/2021 2:36 PM
MZM2511 Warren Buffett - "The stock market is device to transfer money from the impatient to the patient"
21/01/2021 3:44 PM
Aydenlutfi Good bye nexgram. 3cents is coming. Hahahaha
21/01/2021 5:26 PM
SeliparJepon Kucing sapa ni sudah ada tanduk.pisspissss
21/01/2021 9:47 PM
TEEXIANX1840 nexgram last fall, meletup soooooon...
22/01/2021 9:29 AM
OKU_2020 Aydenlutfi@8Dragon... Good bye nexgram. 3cents is coming. Hahahaha
21/01/2021 5:26 PM
++++++++++
YOOOO....smell a rat ( bau tikus) on this cap ayam -holland GN3 ( PN17) Nexgram....
getting worst ,,,no hope

smell a rat >> Meaning : sense that something is not right
Source: theidioms.com
22/01/2021 11:31 AM
MZM2511 OKU_2020
YOOOO....smell a rat ( bau tikus) on this cap ayam -holland GN3 ( PN17) Nexgram....
getting worst ,,,no hope
...................................................

Somebody who aims to buy Nexgram @3 sen is smelling rats, but somebody who aims for BOOM in Nexgram's price in near future will smells flowers. He He
22/01/2021 2:07 PM
8dragon Soon everyone will be welcoming and celebrating Nexgram being promoted to GN3...
22/01/2021 2:31 PM
8dragon Nexgram had been talking about mega projects like cyberjaya, angkasa and trx...all ended up in failure... Now talking about vaccine... can it be a reality and success.. let's wait and see
22/01/2021 2:58 PM
MZM2511 Soon the color of the eyes of 8dragon and OKU_2020 will be in white because Nexgram will never listed as GN3 company in the near future. He He.
22/01/2021 3:00 PM
OKU_2020 8dragon @Soon everyone will be welcoming and celebrating Nexgram being promoted to GN3...
22/01/2021 2:31 PM
+++++++++
YOOOO.....already Kena GN3@PN17 ini Cap Ayam -Holland Nexgram
22/01/2021 3:06 PM
limit_up Someone collecting...
22/01/2021 3:12 PM
MZM2511 8dragon Nexgram had been talking about mega projects like cyberjaya, angkasa and trx...all ended up in failure... Now talking about vaccine... can it be a reality and success.. let's wait and see
------------------------------------------------------------
Rafarma is not manages by 8dragon or OKU_2020, those who always in fear of risks and misleading others about a company that they are always keep looking at. Rafarma, the JV partner of VaccineLab is an American company with a great prospects.

Okay. Let us wait for the results of the JV. Is it a con job by two con companies or it will be a reality???

I'll take a risks and waiting for the rewards.
22/01/2021 3:15 PM
MZM2511 limit_up Someone collecting...
------------------------------------------------
Also there are many potential investors keep waiting to buy @3 sen, and always badmouthing Nexgram to make sure their bad intentions achieved. He He LOL
22/01/2021 3:25 PM
OKU_2020 @8dragon / Aydenlutfi.....sinking ship !
22/01/2021 3:35 PM
MZM2511 @OKU_2020/8dragon/Aydenlutfi. Jual saja kemudian belllahhh.. He He
Tak banyak songeh nanti.
22/01/2021 3:42 PM
8dragon The co is going to reward to those who has been waiting @ 3 cents... is just a matter of time.. just wait patiently. Lol
22/01/2021 3:44 PM
MZM2511 8dragon The co is going to reward to those who has been waiting @ 3 cents... is just a matter of time.. just wait patiently. Lol
-----------------------------------------
If the price reverses to upside without touching low @3 sen, how can "the white eyes" such as 8dragon/OKU_2020/Aydenlutfi can be rewarded. LOL
22/01/2021 3:49 PM
OKU_2020 Help.....help....Tolongg. Makkk...S O S...!
22/01/2021 4:00 PM
MZM2511 @OKU_2020/8dragon/Aydenlutfi. Jual saja kemudian belllahhh.. He He
Tak banyak songeh nanti.
22/01/2021 4:01 PM
TEEXIANX1840 0.040 - 0.045 again
22/01/2021 4:03 PM
8dragon Habis liaw, today close 4 cents
22/01/2021 4:12 PM
OKU_2020 @8dragon Habis liaw, today close 4 cents..
++++++++++
Aiyooo Maaa....Gloomy outlook
22/01/2021 4:17 PM
TunPika Next week game Nexgram.. hehe
22/01/2021 4:58 PM
OKU_2020 Cap Ayam -Holland GN3 ( PN17) Nexgram - ... Lembiq sokmo
22/01/2021 5:07 PM
MZM2511 Operator is collecting Nexgram.. What say you guys?
22/01/2021 5:27 PM
SeliparJepon Barang AAA.wait 3 month lagi.Mau kaya tunggu.Hphone kasi picah.Pasword kasi reset.hahhaah
22/01/2021 5:33 PM
OKU_2020 Many Kena Preqq Sokmo by this GN3 Cap Ayam Nexgram....
22/01/2021 6:10 PM
limit_up Shares changed hand. Operator collecting.
Next week up up up....
22/01/2021 6:23 PM
Monde @Warrant, please support

https://aplabworld.com/

APlab in partnership with Tracvirus-UMBI Care (“TUC”) at UKM Medical Molecular Biology Institute (“UMBI”) for walk-in, and drive-thru COVID-19 test. Get tested by doctor for Covid-19 at home or work place.

” Partnering with Tracvirus means APlab has access to combined over 15,000 PCR test a day across various KKM accredited labs throughout Malaysia. “
22/01/2021 10:59 PM
Monde https://aplabworld.com/about-aplab/
22/01/2021 11:00 PM
Monde Ministry of Health approved RT-PCR laboratory for COVID-19
includes UKM Medical Molecular Biology Institute
(Institut Perubatan Molekul UKM)
22/01/2021 11:03 PM
MZM2511 Good news Monde, and good job Nexgram in adding the company's TracVirus and test kits businesses.
22/01/2021 11:52 PM
saif9545 Wau.. Kucing sudah mau keluar tanduk. Jangan putih mata yee..
23/01/2021 12:20 AM
limit_up Bukan saje keluar tanduk, siap tumbuh sayap.
Nampaknya sudah mau terbang next week...
23/01/2021 8:24 AM
MZM2511 OKU_2020. Warren Buffett - "The stock market is device to transfer money from the impatient to the patient"
23/01/2021 9:03 AM
MZM2511 @OKU_2020. Jual sajalah atau belah sajalah.
GG dok tunggu syarikat tak ada prospek. He He
23/01/2021 9:06 AM
OKU_2020 Beb... Biaq aku jirus ayaq sejuk ( throww cold water ) kat Mamat limit_up yg tengah feeling nii ....
So many times already KENA PREQQQ haaa !!
siok sendiri daaa...
what do you expect from this cap ayam-holland GN3 NexGERAM .
23/01/2021 9:36 AM
MZM2511 OKU_2020. Ambo cuba ingat pengalaman lama. Dulu beli Keladi Maju @ 20 sen lebih. Starked, simpan untuk +- 5 tahun. Pernah turun +- 5 sen. Harga dia lama berada lingkungan 10 sen. SATU HARI TU, TIBA-TIBA mencanak dia naik dan jual terus pada harga +- 40 sen, setelah +- 5 tahun menunggu. Antara pengalaman manis menunggu...
23/01/2021 9:50 AM
OKU_2020 MZM2511 OKU_2020. Ambo cuba ingat pengalaman lama. Dulu beli Keladi Maju @ 20 sen lebih. Starked, simpan untuk +- 5 tahun. Pernah turun +- 5 sen. Harga dia lama berada lingkungan 10 sen. SATU HARI TU, TIBA-TIBA mencanak dia naik dan jual terus pada harga +- 40 sen, setelah +- 5 tahun menunggu. Antara pengalaman manis menunggu...
23/01/2021 9:50 AM
++++++++++++++
Thanks for the joke...tapi ini kisah benar from demo@MZM2511...yg TER_SEKSA @ AZAB saham tersangkut/starked selama 5 tahun...Degree MD ( Doktor Perubatan ) pun siap 5 tahun Beb
ini input bagus for those sifu(s) conducting seminar ( now MCO then webminar)..

You know what is Opportunity Cost ( Kos Melepas ) ??...selama 5 tahun tersangkut saham tuu?..
ni bukan 5 hari beb...tapi 5 tahun daaa...
Gi ambiq texbook Ekonomi Asas SPM waktu anak anda dah tidorr....tidak pun google jerr lagi copeq jangg oiii...!
23/01/2021 2:03 PM
MZM2511 Ambo pernah ngajar ekonomi asas tingkatan 4 dan 5, ajar matrikulasi subjek Ekonomi dan ajar prinsip akaun. Dah lali dah. Tapi lebih baik tanggung kos lepas dari tanggung rugi cut loss. He He
23/01/2021 2:11 PM
MZM2511 8dragon Nexgram had been talking about mega projects like cyberjaya, angkasa and trx...all ended up in failure... Now talking about vaccine... can it be a reality and success.. let's wait and see
--------------------------------------
Tambahan. Sekadar nak kongsi idea yang saya fahami bahawa rakan JV VaccineLab bukanlah sebuah syarikat con, JV dengan VaccineLab dibuat dengan bersungguh-sungguh oleh sebuah syarikat Listed di NYSE yang dalam proses expansion.

Rafarma is in their expansion exercises:

1. They has been merged with BIOCOGENCY LABORATORIES.
Source: https://finance.yahoo.com/news/rafarma-closes-biocogency-merger-131500062.html

2. Rafarma Finalizes Acquisition of Laskavy Patents, Prepared as Global Markets Reset
Source: https://finance.yahoo.com/news/rafarma-finalizes-acquisition-laskavy-patents-165145871.html

3. Rafarma Establishes Thailand Corporate Entity For Merger and Expansion Projects
Source: https://finance.yahoo.com/news/rafarma-establishes-thailand-corporate-entity-151300760.html

4. Rafarma Merger Company Bebig Approved For Production And Sale Of Yttrium-90 For Treatment Of Inoperable Liver Cancer
Source: https://finance.yahoo.com/news/rafarma-merger-company-bebig-approved-141500701.html

5. Rafarma Inks Joint Venture Agreement with Vaccines Lab SDN BHD of Malaysia Source: http://rafarma.si/rafarma-inks-joint-venture-agreement-with-vaccines-lab-sdn-bhd-of-malaysia/
23/01/2021 3:29 PM
MZM2511 Sekadar harapan. Harapan yang disandarkan kepada Rafarma, rakan kongsi JV antara VaccineLab dan Rafarma. Semuanya saya kira berdasarkan bukti yang ada dapat diperoleh. BUKAN SEKADAR ANDAIAN/KENYATAAN KOSONG YANG TANPA FAKTA.
23/01/2021 3:30 PM
OKU_2002 @OKU_2020 hari2 cakap NG cop ayam lah, NG GN3 lah tapi menyemak je kat nexgram i3 tak nak keluar buat apa?. Saja nak tau
23/01/2021 7:19 PM
Singapore88 Besok,,,sikit sikit up
24/01/2021 7:48 PM
SeliparJepon Relax jgn gado2.tomolow operator kasi up sikit.kasi semua happy.TP 0.50 shj.4 bln lagi.hahaha
24/01/2021 9:09 PM
Abd Rahim Osman Makan ubat dulu
Tido awai
Bangun besok... Mana tau jadii KAYA
Nexgram tuju langit
24/01/2021 9:44 PM